BioMed Central reports on the debate over administering working stem cell therapies for heart damage in Germany. Oddly enough, given current restrictive Germany legislation, work appears to be progressing further in Germany than in the US. Here, the FDA simply stepped in to block treatments and human trials. Studies and human trials in the US, Japan and Germany have shown that this therapy works extraordinarily well; it saves lives that would otherwise be lost to heart disease, damage or failure. Despite this evidence, German and US government regulatory bodies are still blocking or attempting to block human trials.